Updated February 27 at 4:27pm
Biotechnology
35 results total, viewing 21 - 30
Dr. Anne S. De Groot, EpiVax CEO and University of Rhode Island professor, has been named one of the most influential people in the vaccine industry by the national vaccine industry organization VaccineNation. more
Tech Collective, Rhode Island’s bioscience and IT industry association, has announced the four winners of its second annual Rhode Island Bioscience Awards. more
Amgen Inc., the world’s biggest biotechnology company by sales, reported second-quarter earnings that beat analysts’ estimates and raised its profit estimate for the year. more
U.S. stocks fluctuated as investors weighed better-than-estimated bank earnings against Federal Reserve concerns about valuations for some social-media and biotech companies. more
U.S. stocks fell a second day from record levels, with the Nasdaq Composite Index tumbling the most since April, as investors sold Internet and biotechnology shares before the start of earnings season. more
Medtronic Inc., the second-largest maker of medical devices, agreed to buy Covidien PLC for $42.9 billion in cash and stock as it transforms into a broader-based company bolstered by new tax advantages. more
Tech Collective, an industry association for information technology and bioscience, has announced a call for applicants for its 2014 Rhode Island Bioscience Awards, the program’s second year following its launch in 2013. more
Nabsys Inc. has begun a search for CEO candidates with experience in life sciences commercialization, as the company moves closer to bringing its high-speed DNA sequencing technology to market, current CEO Dr. Barrett Bready told Providence Business News. more
Global biotech firm Covidien PLC reported Friday that its net income rose five-tenths of a percent in its fiscal second quarter, totaling $441 million, or 97 cents per diluted share, compared with $439 million, or 92 cents per diluted share, during the same period a year earlier. more
Amgen Inc., the world’s largest biotechnology company by revenue, disappointed analysts with lower-than-expected sales of its top drug as executives assured investors the drop was seasonal and they were on target to meet their 2014 projections. more
« Prev | 1 | 2 | 3 | 4 Next »